SMAD3 and carcinoma: SMAD3 is a central component of TGF-β signaling pathway, which has been reported to exerts tumor-suppressive actions that include inhibition of cellular proliferation and immortalization, and in also promotes apoptosis in normal cells and early carcinomas but promotes EMT and procession in various cancer types 34-36.